Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Demoxytocin→

Demoxytocin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
113-78-0
Molecular formula
C43H65N11O12S2
Molecular weight
992.2 g/mol
Drug class
Synthetic oxytocin analogueuterotonic cyclic peptide
Mechanism of action
Activates oxytocin receptors on uterine smooth muscle and mammary myoepithelial cells, increasing intracellular calcium and promoting uterine contractions and milk ejection.
Indications / reported uses
  • Historically used in some countries for induction or augmentation of uterine contractions and to support lactation; current authorisation, obstetric use and safety criteria are jurisdiction-specific

Sources: NLM MeSH — Demoxytocin · PubMed — Demoxytocin oxytocin analogue · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Demoxytocin Environmental Risk Assessment (ERA) (the Demoxytocin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.